Skip to search formSkip to main contentSkip to account menu

pimasertib

Known as: N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4- iodophenyl)amino]isonicotinamide Hydrochloride 
An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (2)

AS 703026MSC1936369
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor
Pimasertib belongs to the growing family of mitogen activated protein kinase (MEK1/2) inhibitors undergoing clinical development… 
2016
2016
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer
KRAS mutations are an established predictor of lack of response to EGFR-targeted therapies in patients with metastatic colorectal… 
2016
2016
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Response
We thank the authors of this letter for their kind comments on our study and for their interesting discussion. However, we do not… 
2015
2015
Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015).
Kidney disease is a complication that is observed in 10%?30% of patients infected with human immunodeficiency virus (HIV), and is… 
2015
2015
THE MEK1/2 INHIBITOR PIMASERTIB ENHANCES GEMCITABINE EFFICACY IN PANCREATIC CANCER MODELS BY ALTERING PROTEIN LEVELS OF RIBONUCLEOTIDE REDUCTASE SUBUNIT-1 (RRM1)
THE MEK1/2 INHIBITOR PIMASERTIB ENHANCES GEMCITABINE EFFICACY IN PANCREATIC CANCER MODELS BY ALTERING PROTEIN LEVELS OF… 
2013
2013
Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
2530 Background: PI3K/mTOR and MAPK signaling pathways are often deregulated in tumors. Simultaneous inhibition of these pathways… 
2013
2013
Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation…
Background: The PI3K/mTOR and MAPK signaling pathways are frequently aberrated in tumors and interact to promote growth. This… 
2013
2013
Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial.
4041 Background: Activating MAPK pathway mutations (predominantly RAS) occur with a high incidence in metastatic pancreatic… 
2013
2013
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
Pancreatic adenocarcinoma is one of the most aggressive malignancies and the fourth leading cause of cancer-related mortality in… 
2012
2012
605 A Phase 1, Open-label, Dose-escalation Study of Oral Administration of the Investigational Agent MLN0128 in Combination with Paclitaxel (P) in Patients (pts) with Advanced Solid Malignancies
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)